索拉非尼对人肝癌细胞生长抑制作用的体外研究

Role of sorafenib on inhibition of growth of human hepatocellular carcinoma cells in vitro

目的:探讨索拉非尼对人肝癌(HCC)细胞体外生长及肿瘤相关基因表达的影响。方法:用不同浓度(0、5、10、20μmol/L)索拉非尼作用人HCC细胞(Hep3B2.1-7)24 h后,用CCK-8法观察细胞的增殖情况,并分别用real-time PCR与Western blot检测各组HCC细胞p53、PTEN、TGF-β1的m RNA与蛋白表达。结果:与0μmol/L索拉非尼处理组(对照组)比较,其余各浓度索拉非尼处理组HCC细胞增殖均明显降低(均P<0.05);p53、PTEN的m RNA与蛋白表达明显升高,而TGF-β1的m RNA与蛋白表达明显降低(均P<0.05),以上作用均呈一定的浓度依赖性。结论:索拉非尼对HCC细胞体外生长有抑制作用,其作用机制与调控肿瘤相关基因的表达有关。

Objective： To investigate the influence of sorafenib on growth and expressions of tumor-related genes in human hepatocellular carcinoma （HCC） cells in vitro. Methods： Human HCC cells （Hep3B2.1-7） were exposed to different concentrations （0, 5, 10, and 20 Frnol/L） of sorafenib for 24 h, and then, the cell proliferation was analyzed by CCK-8 assay, and the mRNA and protein expressions of p53, PTEN and TGF-β1 in the HCC cells were determined by real-time PCR and Western blot, respectively. Results Compared with the group of cells with 0 μmol/L sorafenib treatment （control group）, in the other groups of cells with sorafenib treatment, the cell proliferation rates were all significantly decreased （all P〈0.05）; the mRNA and protein expressions of p53 and PTEN were significantly increased, while the mRNA and protein expressions of TGF-β 1 were significantly decreased （all P〈0.05）. All these effects of sorafenib showed a certain concentration-dependent manner. Conclusion： Sorafenib can inhibit the growth of human HCC ceils in vitro, and the mechanism may be attributed to its regulating the expressions of tumor-related genes